{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T11:58:30Z","timestamp":1776772710049,"version":"3.51.2"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s40121-024-01105-y","type":"journal-article","created":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T18:35:50Z","timestamp":1737052550000},"page":"327-355","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Management of Recurrent Clostridioides difficile Infection (rCDI): A Systematic Literature Review to Assess the Feasibility of Indirect Treatment Comparison (ITC)"],"prefix":"10.1007","volume":"14","author":[{"given":"Johanna Eliasson","family":"Vinterberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Oddsdottir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Nye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4227-7687","authenticated-orcid":false,"given":"Philippe","family":"Pinton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,16]]},"reference":[{"key":"1105_CR1","unstructured":"Mada PK, Alam MU (2023) Clostridioides difficile infection. StatPearls. StatPearls Publishing"},{"issue":"3","key":"1105_CR2","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1053\/j.gastro.2024.01.008","volume":"166","author":"AFKC Peery","year":"2024","unstructured":"Peery AFKC, Kao D, Vaughn BP, Lebwohl B, Singh S, Imdad A, Altayar O. AGA clinical practice guideline on fecal microbiota-based therapies for select gastrointestinal diseases. Gastroenterology. 2024;166(3):409\u201334.","journal-title":"Gastroenterology"},{"key":"1105_CR3","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.cmi.2021.09.038","volume":"27","author":"J van Prehn","year":"2021","unstructured":"van Prehn J, Reigadas E, Vogelzang EH, et al. European society of clinical microbiology and infectious diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults. Clin Microbiol Infect. 2021;27:S1\u201321.","journal-title":"Clin Microbiol Infect"},{"issue":"8","key":"1105_CR4","first-page":"e27979","volume":"14","author":"A Thandavaram","year":"2022","unstructured":"Thandavaram A, Channar A, Purohit A, et al. The efficacy of bezlotoxumab in the prevention of recurrent Clostridium difficile: a systematic review. Cureus. 2022;14(8):e27979.","journal-title":"Cureus"},{"issue":"2","key":"1105_CR5","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3390\/pathogens13020118","volume":"13","author":"JE Markantonis","year":"2024","unstructured":"Markantonis JE, Fallon JT, Madan R, Alam MZ. Clostridioides difficile infection: diagnosis and treatment challenges. Pathogens. 2024;13(2):118.","journal-title":"Pathogens"},{"key":"1105_CR6","doi-asserted-by":"crossref","unstructured":"The next giant step for microbes. Nat Biotechnol. 2023; 41(1):1.","DOI":"10.1038\/s41587-022-01655-x"},{"issue":"15","key":"1105_CR7","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1007\/s40265-022-01797-x","volume":"82","author":"S Khanna","year":"2022","unstructured":"Khanna S, Assi M, Lee C, Yoho D, Louie T, Knapple W, Aguilar H, Garcia-Diaz J, Wang GP, Berry SM, Marion J, Su X, Braun T, Bancke L, Feuerstadt P. Efficacy and safety of RBX2660 in PUNCH CD3, a phase III, randomized, double-blind, placebo-controlled trial with a Bayesian primary analysis for the prevention of recurrent Clostridioides difficile infection. Drugs. 2022;82(15):1527\u201338.","journal-title":"Drugs"},{"issue":"3","key":"1105_CR8","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJMoa2106516","volume":"386","author":"P Feuerstadt","year":"2022","unstructured":"Feuerstadt P, Louie TJ, Lashner B, Wang EEL, Diao L, Bryant JA, Sims M, Kraft CS, Cohen SH, Berenson CS, Korman LY, Ford CB, Litcofsky KD, Lombardo MJ, Wortman JR, Wu H, Aunins JG, McChalicher CWJ, Winkler JA, McGovern BH, Trucksis M, Henn MR, von Moltke L. SER-109, an oral microbiome therapy for recurrent Clostridioides difficile infection. New England J Med. 2022;386(3):220\u20139.","journal-title":"New England J Med"},{"key":"1105_CR9","unstructured":"VE303 for prevention of recurrent Clostridioides difficile infection (RESTORATiVE303). https:\/\/clinicaltrials.gov\/study\/NCT06237452?intr=VE303&rank=2"},{"key":"1105_CR10","unstructured":"Primary or recurrent Clostridioides difficile infection treatment with capsules of lyophilised faecal microbiota vs. fidaxomicin. Accessed 4 Oct 2024. https:\/\/clinicaltrials.gov\/study\/NCT05201079"},{"key":"1105_CR11","unstructured":"Efficacy, safety, and tolerability study of oral full-spectrum MicrobiotaTM (CP101) in subjects with recurrent C. diff (PRISM3). https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03110133"},{"issue":"5","key":"1105_CR12","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1093\/cid\/civ938","volume":"62","author":"ED Dubberke","year":"2016","unstructured":"Dubberke ED, Hardi ER, Kelly R, Mariani C, Misra P, Mullane B, Orenstein K, Pardi R, Price DS, Ramesh CS, Ray MS, Drekonja AD. Safety and durability of RBX2660 (microbiota suspension) for recurrent Clostridium difficile infection: results of the PUNCH CD study. Clin Infect Dis. 2016;62(5):596\u2013602.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"1105_CR13","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1093\/cid\/ciy259","volume":"67","author":"ER Dubberke","year":"2018","unstructured":"Dubberke ER, Lee CH, Orenstein R, Khanna S, Hecht G, Gerding DN. Results from a randomized, placebo-controlled clinical trial of a RBX2660-a microbiota-based drug for the prevention of recurrent Clostridium difficile infection. Clin Infect Dis. 2018;67(8):1198\u20131204.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"1105_CR14","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1093\/ofid\/ofab466.836","volume":"8","author":"TJ Louie","year":"2021","unstructured":"Louie TJ, Sims M, Nathan R, O\u2019Marro S, Kumar PN, Wang EE, Stevens R, Brady K, McGovern B, Moltke LV. Time to recurrence of Clostridioides difficile infection (rCDI) is rapid following completion of standard of care antibiotics: results from ECOSPORIII, a phase 3 double-blind, placebo-controlled randomized trial of SER-109, an investigational microbiome therapeutic. Open Forum Infect Dis. 2021;8(1):422.","journal-title":"Open Forum Infect Dis"},{"key":"1105_CR15","unstructured":"YHEC. Indirect treatment comparison (ITC) https:\/\/yhec.co.uk\/glossary\/indirect-treatment-comparison-itc\/"},{"issue":"2","key":"1105_CR16","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3390\/jmahp12020006","volume":"12","author":"B Macabeo","year":"2024","unstructured":"Macabeo B, Quen\u00e9chdu A, Aball\u00e9a S, Fran\u00e7ois C, Boyer L, Laram\u00e9e P. Methods for indirect treatment comparison: results from a systematic literature review. J Market Access Health Policy. 2024;12(2):58\u201380.","journal-title":"J Market Access Health Policy"},{"key":"1105_CR17","unstructured":"EUnetHTA. Methods guideline D4.3.2 direct and indirect comparisons. 2022. Accessed 18 July 2023. https:\/\/www.eunethta.eu\/wp-content\/uploads\/2022\/08\/EUnetHTA-21-Deliverable-D4.3.2-Methodological-Guideline-on-Direct-and-indirect-comparisons-V1.0.pdf?x69613"},{"issue":"4","key":"1105_CR18","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","volume":"151","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group* T. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Internal Med. 2009;151(4):264\u20139.","journal-title":"Ann Internal Med"},{"issue":"4","key":"1105_CR19","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJMoa1602615","volume":"376","author":"MH Wilcox","year":"2017","unstructured":"Wilcox MH, Gerding DN, Poxton IR, Kelly C, Nathan R, Birch T, Cornely OA, Rahav G, Bouza E, Lee C, Jenkin G, Jensen W, Kim YS, Yoshida J, Gabryelski L, Pedley A, Eves K, Tipping R, Guris D, Kartsonis N, Dorr MB. Bezlotoxumab for prevention of recurrent Clostridium difficile infection. N Engl J Med. 2017;376(4):305\u201317.","journal-title":"N Engl J Med"},{"issue":"12","key":"1105_CR20","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1093\/cid\/ciaa387","volume":"72","author":"BH McGovern","year":"2021","unstructured":"McGovern BH, Ford CB, Henn MR, et al. SER-109, an investigational microbiome drug to reduce recurrence after Clostridioides difficile infection: lessons learned from a phase 2 trial. Clin Infect Dis. 2021;72(12):2132\u201340.","journal-title":"Clin Infect Dis"},{"key":"1105_CR21","unstructured":"Kelly (2022) Efficacy and safety data through week 24 from PRISM3: a randomized, placebo-controlled trial evaluating CP101, an investigational orally administered complete microbiome therapeutic"},{"issue":"16","key":"1105_CR22","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1001\/jama.2023.4314","volume":"329","author":"T Louie","year":"2023","unstructured":"Louie T, Golan Y, Khanna S, et al. VE303, a defined bacterial consortium, for prevention of recurrent Clostridioides difficile infection: a randomized clinical trial. JAMA. 2023;329(16):1356\u201366.","journal-title":"JAMA"},{"issue":"10 Supplement 2","key":"1105_CR23","first-page":"S114","volume":"117","author":"S Khanna","year":"2022","unstructured":"Khanna S, Dubberke ER, Knapple WL, Feuerstadt P, Assi M, Ng S, Guthmueller B, Ando M. Efficacy and safety of RBX2660 in reducing recurrent Clostridioides difficile infection in patients with underlying gastrointestinal comorbidities. Am J Gastroenterol. 2022;117(10 Supplement 2):S114\u20135.","journal-title":"Am J Gastroenterol"},{"issue":"SUPPL 1","key":"1105_CR24","first-page":"S812","volume":"8","author":"TJ Straub","year":"2022","unstructured":"Straub TJ, Diao L, Ford C, Sims M, Louie TJ, Berenson C, Kraft CS, Cohen SH, Paskovaty A, Lombardo MJ, McGovern B, Von Moltke L, Henn M. SER-109, an investigational microbiome therapeutic, reduces abundance of antimicrobial resistance genes in Patients with recurrent Clostridioides difficile infection (rCDI) after standard-of-care antibiotics. Open Forum Infect Dis. 2022;8(SUPPL 1):S812\u20133.","journal-title":"Open Forum Infect Dis"},{"issue":"9","key":"1105_CR25","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1111\/apt.13144","volume":"41","author":"G Cammarota","year":"2015","unstructured":"Cammarota G, Masucci L, Ianiro G, Bibb\u00f2 S, Dinoi G, Costamagna G, Sanguinetti M, Gasbarrini A. Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Therap. 2015;41(9):835\u201343.","journal-title":"Aliment Pharmacol Therap"},{"issue":"3","key":"1105_CR26","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/cid\/ciw731","volume":"64","author":"SS Hota","year":"2017","unstructured":"Hota SS, Sales V, Tomlinson G, Salpeter MJ, McGeer A, Coburn B, Guttman DS, Low DE, Poutanen SM. Oral vancomycin followed by fecal transplantation versus tapering oral vancomycin treatment for recurrent Clostridium difficile infection: an open-label. Clin Infect Dis. 2017;64(3):265\u201371.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"1105_CR27","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1053\/j.gastro.2018.12.019","volume":"156","author":"CL Hvas","year":"2019","unstructured":"Hvas CL, J\u00f8rgensen SMD, J\u00f8rgensen SP, Storgaard M, Lemming L, Hansen MM, Erikstrup C, Dahlerup JF. Fecal microbiota transplantation is superior to fidaxomicin for treatment of recurrent Clostridium difficile infection. Gastroenterology. 2019;156(5):1324\u201332.","journal-title":"Gastroenterology"},{"issue":"2","key":"1105_CR28","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/apt.14816","volume":"48","author":"G Ianiro","year":"2018","unstructured":"Ianiro G, Masucci L, Quaranta G, Simonelli C, Lopetuso LR, Sanguinetti M, Gasbarrini A, Cammarota G. Randomised clinical trial: faecal microbiota transplantation by colonoscopy plus vancomycin for the treatment of severe refractory Clostridium difficile infection-single versus multiple infusions. Aliment Pharmacol Therap. 2018;48(2):152\u20139.","journal-title":"Aliment Pharmacol Therap"},{"issue":"20","key":"1105_CR29","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1001\/jama.2017.17077","volume":"318","author":"D Kao","year":"2017","unstructured":"Kao D, Roach B, Silva M, Beck P, Rioux K, Kaplan GG, Chang HJ, Coward S, Goodman KJ, Xu H, Madsen K, Mason A, Wong GK, Jovel J, Patterson J, Louie T. Effect of oral capsule- vs. colonoscopy-delivered fecal microbiota transplantation on recurrent Clostridium difficile infection: a randomized clinical trial. JAMA. 2017;318(20):1985\u201393.","journal-title":"JAMA"},{"issue":"2","key":"1105_CR30","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1001\/jama.2015.18098","volume":"315","author":"CH Lee","year":"2016","unstructured":"Lee CH, Steiner T, Petrof EO, Smieja M, Roscoe D, Nematallah A, Weese JS, Collins S, Moayyedi P, Crowther M, Ropeleski MJ, Jayaratne P, Higgins D, Li Y, Rau NV, Kim PT. Frozen vs. fresh fecal microbiota transplantation and clinical resolution of diarrhea in patients with recurrent Clostridium difficile infection: a randomized clinical trial. JAMA. 2016;315(2):142\u20139.","journal-title":"JAMA"},{"issue":"9","key":"1105_CR31","doi-asserted-by":"crossref","first-page":"609","DOI":"10.7326\/M16-0271","volume":"165","author":"CR Kelly","year":"2016","unstructured":"Kelly CR, Khoruts A, Staley C, Sadowsky MJ, Abd M, Alani M, Bakow B, Curran P, McKenney J, Tisch A, Reinert SE, Machan JT, Brandt LJ. Effect of fecal microbiota transplantation on recurrence in multiply recurrent Clostridium difficile infection: a randomized trial. Ann Internal Med. 2016;165(9):609\u201316.","journal-title":"Ann Internal Med"},{"key":"1105_CR32","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1093\/ofid\/ofac492.577","volume":"9","author":"P Feuerstadt","year":"2022","unstructured":"Feuerstadt P, Dubberke ER, Guo A, Harvey A, Yang M, Garc\u00eda-Horton V, Fillbrunn M, Tillotson GS, Bancke L, Garey KW. Significant improvement in health-related quality of life (HRQL) with RBX2660: results from a phase 3 randomized, placebo-controlled trial in recurrent Clostridioides difficile infection (PUNCH CD3). Open Forum Infect Dis. 2022;9:2022\u2013110.","journal-title":"Open Forum Infect Dis"},{"issue":"7","key":"1105_CR33","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1111\/apt.13969","volume":"45","author":"ZD Jiang","year":"2017","unstructured":"Jiang ZD, Ajami NJ, Petrosino JF, Jun G, Hanis CL, Shah M, Hochman L, Ankoma-Sey V, DuPont AW, Wong MC, Alexander A, Ke S, DuPont HL. Randomised clinical trial: faecal microbiota transplantation for recurrent Clostridium difficile infection - fresh, or frozen, or lyophilised microbiota from a small pool of healthy donors delivered by colonoscopy. Aliment Pharmacol Therap. 2017;45(7):899\u2013908.","journal-title":"Aliment Pharmacol Therap"},{"issue":"11","key":"1105_CR34","volume":"13","author":"ZD Jiang","year":"2018","unstructured":"Jiang ZD, Jenq RR, Ajami NJ, Petrosino JF, Alexander AA, Ke S, Iqbal T, DuPont AW, Muldrew K, Shi Y, Peterson C, Do KA, DuPont HL. Safety and preliminary efficacy of orally administered lyophilized fecal microbiota product compared with frozen product given by enema for recurrent Clostridium difficile infection: a randomized clinical trial. PLoS ONE. 2018;13(11): e0205064.","journal-title":"PLoS ONE"},{"issue":"11","key":"1105_CR35","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1093\/cid\/ciu135","volume":"58","author":"I Youngster","year":"2014","unstructured":"Youngster I, Sauk J, Pindar C, Wilson RG, Kaplan JL, Smith MB, Alm EJ, Gevers D, Russell GH, Hohmann EL. Fecal microbiota transplant for relapsing Clostridium difficile infection using a frozen inoculum from unrelated donors: a randomized, open-label, controlled pilot study. Clin Infect Dis. 2014;58(11):1515\u201322.","journal-title":"Clin Infect Dis"},{"key":"1105_CR36","doi-asserted-by":"crossref","first-page":"4549298","DOI":"10.1155\/2019\/4549298","volume":"2019","author":"E Garza-Gonz\u00e1lez","year":"2019","unstructured":"Garza-Gonz\u00e1lez E, Mendoza-Olazar\u00e1n S, Morfin-Otero R, Ram\u00edrez-Fontes A, Rodr\u00edguez-Zulueta P, Flores-Trevi\u00f1o S, Bocanegra-Ibarias P, Maldonado-Garza H, Camacho-Ortiz A. Intestinal microbiome changes in fecal microbiota transplant (FMT) vs. FMT enriched with lactobacillus in the treatment of recurrent Clostridioides difficile infection. Can J Gastroenterol Hepatol. 2019:4549298.","journal-title":"Can J Gastroenterol Hepatol"},{"issue":"5","key":"1105_CR37","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1056\/NEJMoa1205037","volume":"368","author":"E Van Nood","year":"2013","unstructured":"Van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, Visser CE, Kuijper EJ, Bartelsman JF, Tijssen JG, Speelman P, Dijkgraaf MG, Keller JJ. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368(5):407\u201315.","journal-title":"N Engl J Med"},{"key":"1105_CR38","doi-asserted-by":"crossref","first-page":"657320","DOI":"10.3389\/fcimb.2021.657320","volume":"11","author":"A Varga","year":"2021","unstructured":"Varga A, Kocsis B, Sipos D, K\u00e1sa P, Vigv\u00e1ri S, P\u00e1l S, Dembrovszky F, Farkas K, P\u00e9terfi Z. How to apply FMT more effectively, conveniently and flexible - a comparison of FMT methods. Front Cell Infect Microbiol. 2021;11:657320.","journal-title":"Front Cell Infect Microbiol"},{"issue":"9","key":"1105_CR39","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/apt.16309","volume":"53","author":"AA Rode","year":"2021","unstructured":"Rode AA, Chehri M, Krogsgaard LR, Heno KK, Svendsen AT, Ribberholt I, Helms M, Engberg J, Schoslashnning K, Tvede M, Andersen CO, Jensen US, Petersen AM, Bytzer P. Randomised clinical trial: a 12-strain bacterial mixture versus faecal microbiota transplantation versus vancomycin for recurrent Clostridioides difficile infections. Aliment Pharmacol Therap. 2021;53(9):999\u20131009.","journal-title":"Aliment Pharmacol Therap"},{"issue":"7","key":"1105_CR40","first-page":"S-650p","volume":"162","author":"C Desjardins","year":"2022","unstructured":"Desjardins C, Bryant JA, Walsh E, Ford CB, Litcofsky KD, Wortman JR, Henn MR. Engraftment of Investigational microbiome therapeutic ser-109 is durable through 24 weeks in a randomized trial (Ecospor Iii) for the treatment of recurrent Clostridioides difficile infection. Conf Proc Gastroenterol. 2022;162(7):S-650.","journal-title":"Conf Proc Gastroenterol"},{"issue":"8","key":"1105_CR41","first-page":"S63","volume":"116","author":"JR Allegretti","year":"2021","unstructured":"Allegretti JR, Kelly CR, Louie T, Fisher M, Hota S, Misra B, Van Hise NW, Yen EF, Bullock JS, Pullman J, Nathan R, Silverman M, Davis I, McGill S, Khanna S, Pardi D, Orenstein R, Grinspan A, El-Nachef N, Kraft CS, Budree S, Borody TJ, Kassam Z. Week 24 efficacy and safety data from PRISM3: a randomized, placebo-controlled trial evaluating CP101, an investigational orally administered microbiome therapeutic for the prevention of recurrent C. difficile infection. Am J Gastroenterol. 2021;116(8):S63\u20134.","journal-title":"Am J Gastroenterol"},{"issue":"17","key":"1105_CR42","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1001\/jama.2014.13875","volume":"312","author":"I Youngster","year":"2014","unstructured":"Youngster I, Russell GH, Pindar C, Ziv-Baran T, Sauk J, Hohmann EL. Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. JAMA. 2014;312(17):1772\u20138.","journal-title":"JAMA J Am Med Assoc"},{"key":"1105_CR43","doi-asserted-by":"crossref","unstructured":"Feuerstadt P, Crawford CV, Tan X, Pokhilko V, Bancke L, Ng S, Guthmueller B, Bidell MR, Tillotson G, Johnson S, Skinner AM. Fecal Microbiota, Live-jslm for the Prevention of Recurrent Clostridioides difficile Infection : Subgroup Analysis of PUNCH CD2 and PUNCH CD3. J Clin Gastroenterol. 2024;58(8):818\u201324.","DOI":"10.1097\/MCG.0000000000001947"},{"issue":"3","key":"1105_CR44","doi-asserted-by":"crossref","first-page":"e1195","DOI":"10.1093\/cid\/ciac554","volume":"76","author":"BG Lapin","year":"2023","unstructured":"Lapin BG, Kevin W, Wu H, Pham SV, Huang SP, Reese PR, Wang E, Deshpande A. Validation of a health-related quality of life questionnaire in patients with recurrent Clostridioides difficile infection in ECOSPOR III, a Phase 3 randomized trial. Clin Infect Dis. 2023;76(3):e1195\u20131201.","journal-title":"Clin Infect Dis"},{"key":"1105_CR45","unstructured":"Phase 2 study of VE303 for prevention of recurrent Clostridium difficile infection (CONSORTIUM). https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03788434"},{"issue":"7","key":"1105_CR46","first-page":"2218","volume":"162","author":"P Feuerstadt","year":"2022","unstructured":"Feuerstadt P, Assi M, Braun T, Su X. Rbx2660 versus placebo to reduce the recurrence of Clostridioides difficile infection: subgroup analysis. Conf Proc Gastroenterol. 2022;162(7):2218.","journal-title":"Conf Proc Gastroenterol"},{"issue":"12","key":"1105_CR47","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1093\/cid\/ciaa387","volume":"72","author":"BHF McGovern","year":"2021","unstructured":"McGovern BHF, Henn CB, Pardi MR, Khanna DS, Hohmann S, O\u2019Brien EL, Desjardins EJ, Bernardo CA, Wortman P, Lombardo JR, Litcofsky MJ, Winkler KD, McChalicher JA, Li CWJ, Tomlinson SS, Nandakumar AD, Cook M, Pomerantz DN, Aunin RJ, Scaron JG, Trucksis M. SER-109 an investigational microbiome drug to reduce recurrence after Clostridioides difficile infection: lessons learned from a phase 2 trial. Clin Infect Dis. 2021;72(12):2132\u201340.","journal-title":"Clin Infect Dis"},{"issue":"7","key":"1105_CR48","doi-asserted-by":"crossref","first-page":"S-651","DOI":"10.1016\/S0016-5085(22)61530-0","volume":"162","author":"S Khanna","year":"2022","unstructured":"Khanna S, Kao DH, Lee C, Ando M, Su X, Braun T. Time to recurrence in patients with Clostridioides difficile infection treated with placebo or Rbx2660. Gastroenterol. 2022;162(7):S-651.","journal-title":"Gastroenterol"},{"issue":"1","key":"1105_CR49","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s12879-022-07256-y","volume":"22","author":"R Orenstein","year":"2022","unstructured":"Orenstein R, Dubberke ER, Khanna S, Lee CH, Yoho D, Johnson S, Hecht G, DuPont HL, Gerding DN, Blount KF, Mische S. Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial. BMC Infect Dis. 2022;22(1):245.","journal-title":"BMC Infect Dis"},{"key":"1105_CR50","first-page":"175628482311742","volume":"16","author":"C Lee","year":"2023","unstructured":"Lee C, Louie T, Bancke L, Guthmueller B, Harvey A, Feuerstadt P, Khanna S, Orenstein R, Dubberke ER. Safety of fecal microbiota, live-jslm (REBYOTATM) in individuals with recurrent Clostridioides difficile infection: data from five prospective clinical trials. Therap Adv Gastroenterol. 2023;16:1\u201316.","journal-title":"Therap Adv Gastroenterol"},{"issue":"8","key":"1105_CR51","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1177\/2050640619854587","volume":"7","author":"T Rokkas","year":"2019","unstructured":"Rokkas T, Gisbert JP, Gasbarrini A, et al. A network meta-analysis of randomized controlled trials exploring the role of fecal microbiota transplantation in recurrent Clostridium difficile infection. United Eur Gastroenterol J. 2019;7(8):1051\u201363.","journal-title":"United Eur Gastroenterol J"},{"key":"1105_CR52","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1001\/jamainternmed.2015.4114","volume":"175","author":"CR Polage","year":"2015","unstructured":"Polage CR, Gyorke CE, Kennedy MA, Leslie JL. Overdiagnosis of Clostridium difficile infection in the molecular test era. JAMA Intern Med. 2015;175:1792\u2013801.","journal-title":"JAMA Intern Med"},{"key":"1105_CR53","doi-asserted-by":"crossref","first-page":"100642","DOI":"10.1016\/j.eclinm.2020.100642","volume":"29","author":"SMD Baunwall","year":"2020","unstructured":"Baunwall SMD, Lee MM, Eriksen MK, et al. Faecal microbiota transplantation for recurrent Clostridioides difficile infection: an updated systematic review and meta-analysis. EClinicalMedicine. 2020;29-30:100642.","journal-title":"EClinicalMedicine."},{"key":"1105_CR54","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/MCG.0000000000001667","volume":"57","author":"ASS Beran","year":"2023","unstructured":"Beran ASS, Ghazaleh S, et al. Predictors of fecal microbiota transplant failure in Clostridioides difficile infection: an updated meta-analysis. J Clin Gastroenterol. 2023;57:389\u201399.","journal-title":"J Clin Gastroenterol"},{"key":"1105_CR55","doi-asserted-by":"crossref","first-page":"61","DOI":"10.5009\/gnl20135","volume":"15","author":"HSH Yoon","year":"2021","unstructured":"Yoon HSH, Seol M, et al. Factors related to outcomes of fecal microbiota transplantation in patients with Clostridioides difficile infection. Gut Liver. 2021;15:61\u20139.","journal-title":"Gut Liver"},{"issue":"4","key":"1105_CR56","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.cmi.2023.12.007","volume":"30","author":"N Benech","year":"2024","unstructured":"Benech N, Barbut F, Fitzpatrick F, et al. Update on microbiota-derived therapies for recurrent Clostridioides difficile infections. Clin Microbiol Infect. 2024;30(4):462\u20138.","journal-title":"Clin Microbiol Infect"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-024-01105-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-024-01105-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-024-01105-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T17:57:15Z","timestamp":1739642235000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-024-01105-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,16]]},"references-count":56,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["1105"],"URL":"https:\/\/doi.org\/10.1007\/s40121-024-01105-y","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,16]]},"assertion":[{"value":"12 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Johanna Eliasson Vinterberg is an employee of Ferring Pharmaceuticals; Julia Oddsdottir and Maria Nye are employees of IQVIA. IQVIA received funding from Ferring Pharmaceuticals for running the study; Philippe Pinton is an employee of Ferring Pharmaceuticals, belongs to the board of directors of PharmaBiome, and owns stocks in Takeda Pharmaceutical Company Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was a review of previously published literature and did not involve human subjects. Therefore, ethical approval was not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}